quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·766d
PRRelease
First Wave BioPharma Inc. logo

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

FWBI· First Wave BioPharma Inc.
Health Care
Original source

Companies

  • FWBI
    First Wave BioPharma Inc.
    Health Care

Recent analyst ratings

  • Dec 7UpdateMaxim Group-

Related

  • NEWS707d
    First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
  • SEC707d
    First Wave BioPharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR707d
    First Wave BioPharma Changes Name to Entero Therapeutics
  • SEC709d
    SEC Form 10-Q filed by First Wave BioPharma Inc.
  • SEC710d
    First Wave BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC710d
    SEC Form 424B5 filed by First Wave BioPharma Inc.
  • NEWS713d
    First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
  • PR713d
    First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022